What is he best known for?
The fields of study he is best known for:
His primary areas of study are Cancer research, Apoptosis, Programmed cell death, Cell biology and Signal transduction.
The Cancer research study combines topics in areas such as XIAP, Chronic lymphocytic leukemia, Leukemia, Immunology and Tumor progression.
His Apoptosis study combines topics in areas such as Cancer and Mitochondrion.
His work in Programmed cell death tackles topics such as TRAF4 which are related to areas like Protein structure, TRAF1, TRAF2, SPOP and Peptide sequence.
His research investigates the connection with Cell biology and areas like CD40 which intersect with concerns in Tumor necrosis factor alpha, Cell–cell interaction, Follicular dendritic cells, Cell adhesion molecule and Dendritic cell.
His Signal transduction research is multidisciplinary, relying on both Tumor Necrosis Factor Receptor-Associated Factors and Trk receptor, Neurotrophin.
His most cited work include:
- Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses (621 citations)
- Immunohistochemical Analysis of in Vivo Patterns of Expression of CPP32 (Caspase-3), a Cell Death Protease (414 citations)
- The Bioenergetic Signature of Cancer: A Marker of Tumor Progression (374 citations)
What are the main themes of his work throughout his whole career to date?
Juan M. Zapata spends much of his time researching Cancer research, Molecular biology, Cell biology, Apoptosis and Chronic lymphocytic leukemia.
His Cancer research research is multidisciplinary, incorporating perspectives in XIAP, Immunology, Cancer immunotherapy, Signal transduction and Programmed cell death.
His Molecular biology study integrates concerns from other disciplines, such as Heat shock protein, Cell culture, B cell and Receptor, TRAF3.
The Cell biology study combines topics in areas such as Cell cycle, Ubiquitin and Cell–cell interaction.
His study looks at the relationship between Apoptosis and topics such as Immunohistochemistry, which overlap with Bcl-2 family.
His studies in Chronic lymphocytic leukemia integrate themes in fields like B-cell lymphoma, B-cell activating factor and In vivo.
He most often published in these fields:
- Cancer research (38.83%)
- Molecular biology (34.95%)
- Cell biology (28.16%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (38.83%)
- B cell (16.50%)
- T cell (8.74%)
In recent papers he was focusing on the following fields of study:
Cancer research, B cell, T cell, B-cell lymphoma and Molecular biology are his primary areas of study.
His Cancer research study combines topics from a wide range of disciplines, such as Cell culture, Systemic administration, CD8, Cancer immunotherapy and Receptor.
His work deals with themes such as Cancer and Interleukin 15, which intersect with Receptor.
His T cell research incorporates elements of T-cell leukemia and Kinase, TRAF3.
His B-cell lymphoma research includes elements of Chronic lymphocytic leukemia, [email protected], Immunoglobulin D, breakpoint cluster region and B-cell activating factor.
Molecular biology and Plasma cell neoplasm are two areas of study in which Juan M. Zapata engages in interdisciplinary work.
Between 2017 and 2021, his most popular works were:
- A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. (49 citations)
- CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs. (27 citations)
- Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice (7 citations)
In his most recent research, the most cited papers focused on:
Juan M. Zapata focuses on Immunoglobulin D, Molecular biology, B-cell lymphoma, B cell homeostasis and B cell.
His studies deal with areas such as Gene rearrangement, Somatic hypermutation and Diffuse large B-cell lymphoma as well as Immunoglobulin D.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
